Cargando…

Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation

Pneumococcal disease is a potentially fatal bacterial infection that is vaccine-preventable. Malaysia has yet to adopt a pneumococcal conjugate vaccine (PCV) into its national immunization program (NIP). In 2016, pneumonia was the 3(rd) leading cause of death in children under five in Malaysia, acco...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafie, Asrul Akmal, Ahmad, Norazah, Naidoo, Jerusha, Foo, Chee Yoong, Wong, Callix, Pugh, Sarah, Tan, Kah Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482775/
https://www.ncbi.nlm.nih.gov/pubmed/31951782
http://dx.doi.org/10.1080/21645515.2019.1701911
_version_ 1783580844546326528
author Shafie, Asrul Akmal
Ahmad, Norazah
Naidoo, Jerusha
Foo, Chee Yoong
Wong, Callix
Pugh, Sarah
Tan, Kah Kee
author_facet Shafie, Asrul Akmal
Ahmad, Norazah
Naidoo, Jerusha
Foo, Chee Yoong
Wong, Callix
Pugh, Sarah
Tan, Kah Kee
author_sort Shafie, Asrul Akmal
collection PubMed
description Pneumococcal disease is a potentially fatal bacterial infection that is vaccine-preventable. Malaysia has yet to adopt a pneumococcal conjugate vaccine (PCV) into its national immunization program (NIP). In 2016, pneumonia was the 3(rd) leading cause of death in children under five in Malaysia, accounting for 3.8% of under-five deaths. Introducing a pneumococcal conjugate vaccine (PCV) is an effective strategy to reduce the disease burden. This study used a decision-analytic model to assess the potential impacts of introducing the available PCVs (13-valent and 10-valent) in Malaysia. Epidemiological and costs inputs were sourced from published literature. For each vaccination program, health outcomes and associated healthcare costs were estimated. The scenarios of initiating PCV13 vs. PCV10 and the status quo (no pneumococcal vaccine) were compared. Serotype trends of Finland and the U.K. were used to model the clinical impacts of PCV10 and PCV13 respectively. The base-case analysis used a societal perspective over a 5-year time horizon. Compared with PCV10, PCV13 was projected to avert an additional 190,628 cases of pneumococcal disease and 1126 cases of death. The acquisition of PCV13 was estimated to cost an incremental US$89,904,777, offset by a cost reduction of -US$250,219,914 on pneumococcal disease-related medical care and lost productivity. PCV13 demonstrated a higher cost-saving potential over PCV10. Compared with no vaccination, PCV13 was estimated as cost-saving. Results were robust across a series of sensitivity analyses. The introduction of PCV13 in a NIP was estimated to reduce a significant burden of disease and to be a cost-saving for the Malaysian health system.
format Online
Article
Text
id pubmed-7482775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74827752020-09-16 Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation Shafie, Asrul Akmal Ahmad, Norazah Naidoo, Jerusha Foo, Chee Yoong Wong, Callix Pugh, Sarah Tan, Kah Kee Hum Vaccin Immunother Research Paper Pneumococcal disease is a potentially fatal bacterial infection that is vaccine-preventable. Malaysia has yet to adopt a pneumococcal conjugate vaccine (PCV) into its national immunization program (NIP). In 2016, pneumonia was the 3(rd) leading cause of death in children under five in Malaysia, accounting for 3.8% of under-five deaths. Introducing a pneumococcal conjugate vaccine (PCV) is an effective strategy to reduce the disease burden. This study used a decision-analytic model to assess the potential impacts of introducing the available PCVs (13-valent and 10-valent) in Malaysia. Epidemiological and costs inputs were sourced from published literature. For each vaccination program, health outcomes and associated healthcare costs were estimated. The scenarios of initiating PCV13 vs. PCV10 and the status quo (no pneumococcal vaccine) were compared. Serotype trends of Finland and the U.K. were used to model the clinical impacts of PCV10 and PCV13 respectively. The base-case analysis used a societal perspective over a 5-year time horizon. Compared with PCV10, PCV13 was projected to avert an additional 190,628 cases of pneumococcal disease and 1126 cases of death. The acquisition of PCV13 was estimated to cost an incremental US$89,904,777, offset by a cost reduction of -US$250,219,914 on pneumococcal disease-related medical care and lost productivity. PCV13 demonstrated a higher cost-saving potential over PCV10. Compared with no vaccination, PCV13 was estimated as cost-saving. Results were robust across a series of sensitivity analyses. The introduction of PCV13 in a NIP was estimated to reduce a significant burden of disease and to be a cost-saving for the Malaysian health system. Taylor & Francis 2020-01-17 /pmc/articles/PMC7482775/ /pubmed/31951782 http://dx.doi.org/10.1080/21645515.2019.1701911 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Shafie, Asrul Akmal
Ahmad, Norazah
Naidoo, Jerusha
Foo, Chee Yoong
Wong, Callix
Pugh, Sarah
Tan, Kah Kee
Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title_full Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title_fullStr Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title_full_unstemmed Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title_short Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation
title_sort estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in malaysia- an economic evaluation
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482775/
https://www.ncbi.nlm.nih.gov/pubmed/31951782
http://dx.doi.org/10.1080/21645515.2019.1701911
work_keys_str_mv AT shafieasrulakmal estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT ahmadnorazah estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT naidoojerusha estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT foocheeyoong estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT wongcallix estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT pughsarah estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation
AT tankahkee estimatingthepopulationhealthandeconomicimpactsofintroducingapneumococcalconjugatevaccineinmalaysiaaneconomicevaluation